Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacy

Biomaterials

Volumn 34, Issue 33, 2013, Pages 8424-8429

  Chu, Kevin S ^a   Schorzman, Allison N ^a   Finniss, Mathew C ^a   Bowerman, Charles J ^a   Peng, Lei ^a   Luft, James C ^a   Madden, Andrew J ^a   Wang, Andrew Z ^a,b   Zamboni, William C ^a,b,c   DeSimone, Joseph M ^a,b,c,d,e  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of North Carolina   (United States)

^d North Carolina State University   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Docetaxel; Drug loading; Pharmacokinetics; Polylactic acid; Soft lithography

Indexed keywords

DOCETAXEL; DRUG LOADING; FABRICATION TECHNIQUE; PHARMACOKINETIC PROFILES; PHARMACOKINETIC PROPERTIES; POLY LACTIC ACID; SOFT-LITHOGRAPHY; THERAPEUTIC EFFICACY;

NANOPARTICLES; SURFACE CHEMISTRY;

PHARMACOKINETICS;

DOCETAXEL; NANOPARTICLE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER; LUNG; LUNG ADENOCARCINOMA; LUNG ALVEOLUS; MAXIMUM TOLERATED DOSE; MOLECULAR SIZE; MOLECULAR WEIGHT; MOUSE; NANOFABRICATION; NONHUMAN; PLASMA; PRIORITY JOURNAL; SPLEEN; TUMOR XENOGRAFT;

MURINAE;

DOCETAXEL; DRUG LOADING; PHARMACOKINETICS; POLYLACTIC ACID; SOFT-LITHOGRAPHY;

ANIMALS; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, NUDE; NANOPARTICLES; POLYMERS; TANDEM MASS SPECTROMETRY; TAXOIDS;

EID: 84881661205     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.07.038     Document Type: Article

References (24)

1. Tang L., Fan F.M., Borst L.B., Cheng J. Synthesis and biological response of size-specific, monodisperse drug-silica nanoconjugates. ACS Nano 2003, 6:3954-3966.
2. Chu K.S., Hasan W., Rawal S., Walsh M.D., Enlow E.M., Luft J.C., et al. Plasma, tumor and tissue pharmacokinetics of docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine 2013, 9:686-693.
3. Chauhan V.P., Popović Z., Chen O., Cui J., Fukumura D., Bawendi M.G., et al. Fluorescent nanorods and nanospheres for real-time invivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl 2011, 50:11417-11420.
4. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., et al. Accumulation of sub-100nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol 2011, 6:815-823.
5. Smith B.R., Kempen P., Bouley D., Xu A., Liu Z., Melosh N., et al. Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett 2012, 12:3369-3377.
6. Campbell R.B., Fukumura D., Brown E.B., Mazzola L.M., Izumi Y., Jain R.K., et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002, 62:6831-6836.
7. Hrkach J., Von Hoff D., Ali M.M., Andrianova E., Auer J., Campbell T., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:128ra39.
8. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., et al. Formulation of functionalized PLGA-PEG nanoparticles for invivo targeted drug delivery. Biomaterials 2007, 28:869-876.
9. Dong X., Mattingly C.A., Tseng M.T., Cho M.J., Liu Y., Adams V.R., et al. Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP. Cancer Res 2009, 69:3918-3926.
10. Tardi P.G., Gallagher R.C., Johnstone S., Harasym N., Webb M., Bally M.B., et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release invivo. Biochim Biophys Acta 2007, 1768:678-687.
11. Dicko A., Kwak S., Frazier A.A., Mayer L.D., Liboiron B.D. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int J Pharm 2010, 391:248-259.
12. Yu Y., He Y., Xu B., He Z., Zhang Y., Chen Y., et al. Self-assembled methoxy poly(ethylene glycol)-cholesterol micelles for hydrophobic drug delivery. JPharm Sci 2012, 102:1-9.
13. Enlow E.M., Luft J.C., Napier M.E., DeSimone J.M. Potent engineered PLGA nanoparticles by virtue of exceptionally high chemotherapeutic loadings. Nano Lett 2011, 11:808-813.
14. Peng L., Feng L., Benhabbour S.R., Mumper R.J. Development of a novel orthotopic non-small cell lung cancer model and therapeutic benefit of 2'-(2-bromohexadecanoyl)-docetaxel conjugate nanoparticles 2013, in press.
15. Walsh M.D., Hanna S.K., Sen J., Rawal S., Cabral C.B., Yurkovetskiy A.V., et al. Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts. Clin Cancer Res 2012, 18:2591-2602.
16. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 2006, 12:1317-1324.
17. Desai N.P., Trieu V., Hwang L.Y., Wu R., Soon-Shiong P., Gradishar W.J. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008, 19:899-909.
18. Kim S.C., Kim D.W., Shim Y.H., Bang J.S., Oh H.S., Wan Kim S., et al. Invivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. JControl Release 2001, 72:191-202.
19. Dave J., Patel H.M. Differentiation in hepatic and splenic phagocytic activity during reticuloendothelial blockade with cholesterol-free and cholesterol-rich liposomes. Biochim Biophys Acta 1986, 888:184-190.
20. Gabizon A., Tzemach D., Mak L., Bronstein M., Horowitz A.T. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. JDrug Target 2002, 10:539-548.
21. Panagi Z., Beletsi A., Evangelatos G., Livaniou E., Ithakissios D.S., Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles. Int J Pharm 2001, 221:143-152.
22. Patel H.M., Tuzel N.S., Ryman B.E. Inhibitory effect of cholesterol on the uptake of liposomes by liver and spleen. Biochim Biophys Acta 1983, 761:142-151.
23. Allen T.M., Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta 1991, 1068:133-141.
24. Souhami R.L., Patel H.M., Ryman B.E. The effect of reticuloendothelial blockade on the blood clearance and tissue distribution of liposomes. Biochim Biophys Acta 1981, 674:354-371.